Effects of SGLT2 inhibitor combined with sacubitril valsartan sodium on VEGF NT-proBNP and exercise tolerance in patients with chronic heart failure
Objective To investigate the effects of sodium-dependent glucose transporters 2(SGLT2)inhibitor combined with sacubitril valsartan sodium on vascular endothelial growth factor(VEGF),N-terminal pro brain natriuretic peptide(NT-proBNP),and exercise tolerance in patients with chronic heart failure.Methods A total of 92 patients with chronic heart failure(admitted to our hospital from January 2023 to January 2024)were randomly divided into the observation group and the control group with 46 cases in each group by drawing lot method.The control group was treated with sacubatrotril valsartan sodium,while the observation group was treated with SGLT2 inhibitor(dagaglizin)on the basis of the control group.For 3 months,the efficacy of cytokines[serum cardiac troponin I(cTnI),VEGF,NT-proBNP]and exercise tolerance[exercise duration,exercise metabolic equivalent and 6-minute walking test(6MWT)]were compared between the two groups.Results After treatment,the effective rate between the observation group and the control group was 98.0%vs 85.0%(P＜0.05).The levels of cTnI,VEGF and NT-proBNP in both groups were decreased compared with those before treatment,and the decrease was more significant in observation group(P＜0.05).Exercise time,exercise metabolic equivalent and 6MWT in both groups were increased compared with those before treatment,and the increases were more significant in observation group(P＜0.05).Conclusion The application of SGLT2 inhibitor combined with sacubitril valsartan sodium in the treatment of chronic heart failure patients can effectively improve the levels of cTnI,VEGF and NT-proBNP,promote the repair of myocardial injury,the cardiac function,and the recovery of exercise tolerance,with good efficacy.
万方数据
维普
